Research analysts who have asked questions during BioLineRx earnings calls.
JV
John Vandermosten
Zacks Small Cap Research
5 questions for BLRX
Also covers: ACHV, BIOR, DYAI +10 more
Joseph Pantginis
H.C. Wainwright & Co.
3 questions for BLRX
Also covers: ARMP, BCDA, BYSI +15 more
JW
Justin Walsh
Jones Trading
3 questions for BLRX
Also covers: ACHV, GTBP, LNTH +6 more
JP
Joe Pantginis
H.C. Wainwright
2 questions for BLRX
Recent press releases and 8-K filings for BLRX.
BioLineRx Reports Q3 2025 Financials and Announces GlyxOne Joint Venture
BLRX
Earnings
New Projects/Investments
- BioLineRx reported total revenues of $0.4 million and a net loss of $1 million for the third quarter of 2025. The company held $25.2 million in cash, cash equivalents, and short-term bank deposits as of September 30, 2025, which is sufficient to fund operations into the first half of 2027.
- The company established a Joint Venture with Hemispherian to develop GlyxOne, a molecule for glioblastoma and other cancers, with a first-in-human phase 1/2a glioblastoma trial planned for Q1 2026. BioLineRx holds a 40% stake in the JV and will consolidate its expenses in its financial statements.
- GlyxOne's patent protection was strengthened with a new U.S. PTO allowance covering its use in up to 90% of all cancers, extending protection until 2040, with other patents valid until at least 2040 and a pending international patent until at least 2044.
- Positive final results from a Phase 1 trial of metixafortide in sickle cell disease, demonstrating safe and robust hematopoietic stem cell mobilization, are scheduled for presentation at the ASH annual meeting in December. The chemoformet-PANC Phase 2b trial for metixafortide in pancreatic cancer continues to enroll patients.
Nov 24, 2025, 1:30 PM
BioLineRx Announces Q3 2025 Financial Results and GLIX1 Development Plans
BLRX
Earnings
New Projects/Investments
- BioLineRx established a Joint Venture (JV) with Hemispherian to develop GLIX1 for glioblastoma and other cancers, with a Phase 1/2a trial planned for Q1 2026 following FDA IND clearance in August.
- The company reported total revenues of $0.4 million and a net loss of $1 million for the third quarter of 2025.
- As of September 30, 2025, BioLineRx held $25.2 million in cash and equivalents, which is expected to fund operations into the first half of 2027.
- Positive final results from a Phase 1 investigator-initiated trial of metixafortide in sickle cell disease were announced, demonstrating robust hematopoietic stem cell mobilization and safety.
Nov 24, 2025, 1:30 PM
BioLineRx Reports Q3 2025 Financial Results and Corporate Update
BLRX
Earnings
New Projects/Investments
Guidance Update
- BioLineRx reported a net loss of $1.0 million for the third quarter of 2025, with total revenues of $0.4 million.
- As of September 30, 2025, the company had $25.2 million in cash, cash equivalents, and short-term bank deposits, maintaining its cash runway guidance into the first half of 2027.
- A joint venture was established with Hemispherian AS to advance GLIX1, a small molecule cancer therapeutic, with a Phase 1/2a clinical trial expected to commence in Q1 2026.
- APHEXDA generated sales of $2.4 million in the third quarter of 2025, providing $0.4 million in royalty revenue to BioLineRx.
Nov 24, 2025, 12:00 PM
BioLineRx Receives USPTO Patent Allowance for GLIX1
BLRX
New Projects/Investments
- BioLineRx Ltd. announced on November 17, 2025, the receipt of a U.S. Patent and Trademark Office (USPTO) Notice of Allowance for a key patent covering GLIX1.
- This patent covers the use of GLIX1 for treating cancer types where cytidine deaminase (CDA) is not over-expressed, which is estimated to represent over 90% of all cancers.
- The allowance broadens and strengthens GLIX1's patent protection until 2040, with a possible patent-term extension of up to five years.
- A first-in-human study of GLIX1 in patients with glioblastoma is expected to be initiated in the first quarter of 2026, with plans to expand development into other cancer types.
Nov 17, 2025, 12:12 PM
BioLineRx Receives Key Patent Allowance for GLIX1 Cancer Treatment
BLRX
New Projects/Investments
- BioLineRx announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent covering GLIX1 for treating cancers where cytidine deaminase (CDA) is not over-expressed, representing over 90% of all cancers.
- This patent significantly broadens and strengthens GLIX1's intellectual property estate, providing patent protection until 2040, with a possible extension of up to five years.
- The company plans to initiate a first-in-human study of GLIX1 in glioblastoma patients in the first quarter of 2026.
Nov 17, 2025, 12:00 PM
BioLineRx Provides Update on GLIX1 Development, APHEXDA Licensing, and Financial Outlook
BLRX
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- BioLineRx has formed a Joint Venture with Hemispherian AS to develop GLIX1, a new asset with FDA-approved IND status, with Phase 1 development expected to begin in H1 2026 for glioblastoma and other cancers. The estimated total addressable market for glioblastoma in major markets is projected to be >$3.7 billion by 2030.
- The company has successfully out-licensed APHEXDA, an FDA-approved drug, through agreements with Gamida Cell and Gloria Biosciences, which could generate up to $87 million and $200 million respectively in commercial milestones, in addition to royalties on sales.
- As of June 30, 2025, BioLineRx reported ~$28.2 million in cash, providing a cash runway into the first half of 2027.
- Key upcoming milestones include the initiation of the Phase 1/2a GLIX1 trial in Q1 2026 and the release of data from the Phase 1 part of the GLIX1 trial in H1 2027.
Sep 29, 2025, 12:30 PM
BioLineRx and Hemispherian AS Form Joint Venture to Develop GLYCS1
BLRX
New Projects/Investments
M&A
- BioLineRx and Hemispherian AS have established a joint venture to develop GLYCS1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers.
- BioLineRx will hold an initial 40% stake in the joint venture, with the potential to increase to 70% through continued investment, and will be responsible for managing and funding development activities.
- The joint venture plans to initiate a Phase 1-2A clinical trial for GLYCS1 in glioblastoma in the first quarter of 2026, with data from the Phase 1 part anticipated in the first half of 2027.
- GLYCS1 has received Orphan Drug Designation from both the FDA and EMA, and its patents are valid until at least 2040 with potential extensions.
- BioLineRx's current cash runway extends into the first half of 2027, incorporating the contemplated investment in GLYCS1.
Sep 29, 2025, 12:30 PM
BioLineRx and Hemispherian Establish Joint Venture for GLIX1 Development
BLRX
M&A
New Projects/Investments
Product Launch
- BioLineRx Ltd. and Hemispherian AS have formed a joint venture (JV) to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers.
- Hemispherian will initially hold 60% of the JV's share capital, and BioLineRx will hold 40%. BioLineRx has committed to invest $5 million within 36 months, with the potential to increase its ownership to a maximum of 70% through additional investments.
- BioLineRx will manage the JV's development activities, operations, budget, and expenses. The JV will pay Hemispherian a monthly advisory fee of $80,000 for up to 24 months.
- An FDA Investigational New Drug (IND) application for GLIX1 was cleared in August 2025, and a Phase 1/2a study is expected to initiate in Q1 2026. Data from the Phase 1 part of the trial is anticipated in H1 2027.
- The glioblastoma market opportunity is estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030. BioLineRx affirms its cash runway into the first half of 2027.
Sep 29, 2025, 11:12 AM
BioLineRx and Hemispherian Establish Joint Venture for GLIX1 Development
BLRX
M&A
New Projects/Investments
- BioLineRx Ltd. and Hemispherian AS have established a joint venture to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers.
- The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for GLIX1 in August 2025, with a Phase 1/2a study expected to initiate in Q1 2026.
- The glioblastoma market opportunity is estimated to exceed $3.8 billion annually across the US and EU5 by 2030.
- Hemispherian will contribute global rights to GLIX1 and hold 60% of the JV's share capital, while BioLineRx will be responsible for funding development activities and hold a 40% stake, potentially increasing to a maximum of 70% with continued investment.
- BioLineRx affirms its cash runway into the first half of 2027.
Sep 29, 2025, 11:00 AM
Quarterly earnings call transcripts for BioLineRx.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more